Our Story

Lilly Ventures has its roots in
the scientific tradition of
Eli Lilly and Company. Our
investment philosophy drives
us to seek great companies
with compelling life science innovations.

Our Team

Our collaborative partnership leverages the collective experience, deep expertise, and networks of our investment professionals for the benefit of our portfolio companies.

Aileron appoints Vice President of Clinical Development
September 06 2012

Aileron Therapeutics, Inc. announced the appointment of Hubert C. Chen, M.D., to Vice President of Clinical Development, Endocrine and Metabolic Disease.

view full story

FORMA Therapeutics appoints Chief Business Officer
September 05 2012

FORMA Therapeutics announced the appointment of Rob Sarisky, Ph.D. to Chief Business Officer. Dr. Sarisky most recently served as Vice President of Oncology Business Development and Licensing at Janssen Pharmaceuticals.

view full story

InnoCentive and AARP Foundation Team Up to Improve Lives
July 24 2012

InnoCentive, Inc. announced a collaboration with AARP Foundation, AARP's charitable affiliate, to help advance the Foundation's cause of improving the lives of millions of older Americans who struggle to meet their basic needs for nutritious food, safe and affordable housing, adequate income, and personal connections.

view full story

Cerulean Announces First Patient Dosed in Phase 2 Study in Ovarian Cancer
July 23 2012

Cerulean Pharma Inc. announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

view full story

Receptos Publishes G-Protein Coupled Receptor Structure in Science
July 12 2012

Receptos Inc. announced the co-publication, with The Scripps Research Institute, of high resolution G-protein coupled receptor (GPCR) crystal structures in Science. This will enable rational drug discovery and design of GPCRs.

view full story

Cerulean Completes Enrollment of Phase 2 Study in Non-Small Cell Lung Cancer
July 02 2012

Cerulean Pharma Inc. announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC) patients.

view full story

Cerulean Announces First Patient Dosed in Phase 1b/2a Study in Combination with Avastin in Renal Cancer
July 02 2012

Cerulean Pharma Inc. announced the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients.

view full story

FORMA Therapeutics Partners with TGen Drug Development (TD2)
July 02 2012

FORMA Therapeutics and TGen Drug Development (TD2) announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

view full story

Viamet Pharmaceuticals Announces Agreement with NIAID
June 19 2012

Viamet Pharmaceuticals, Inc. announced that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAID’s preclinical services program to develop broad-spectrum antifungal agents.

view full story

Protagonist Therapeutics and Zealand Pharma Enter Drug Discovery Collaboration
June 18 2012

Protagonist entered into a collaboration agreement with Zealand Pharma to identify novel peptide drug candidates by utilizing Zealand Pharma’s expertise in peptide optimization technology.

view full story

Sutro Closes $16.5 Million Second Tranche of Series C Financing
May 08 2012

Sutro Biopharma announced the closing of the $16.5 million second tranche of its Series C financing. This funding will be utilized to develop next generation antibody drug conjugates and bi-specific antibody platforms.

view full story

Viamet Pharmaceuticals Appoints Chief Business and Financial Officer
March 07 2012

Viamet Pharmaceuticals, Inc. announced the appointment of Richard D. Katz, M.D. to the newly created position of Chief Business and Financial Officer. Dr. Katz will be responsible for strategic planning and direction, overseeing commercial and financial operations and execution of the company’s corporate and business development activities.

view full story

Hydra and Zalicus Collaborate on Novel Ion Channel Candidates for the Treatment of Pain
February 09 2012

Zalicus Inc. and Hydra Biosciences, Inc. announced that they have entered into a collaboration to advance development of Zalicus’ preclinical ion channel modulator product candidates for the treatment of pain.

view full story

InnoCentive Acquires OmniCompete Ltd.
February 06 2012

InnoCentive, Inc. announced its acquisition of UK-based OmniCompete Limited. OmniCompete, well known for its annual Global Security Challenge, has executed nearly two dozen high-profile Challenges in the areas of security, energy, healthcare, and cloud computing.

view full story

Cerulean Pharma Appoints Chief Business Officer
January 23 2012

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the appointment of Chris Guiffre as Senior Vice President and Chief Business Officer, a newly created position.

view full story

FORMA Therapeutics Announces Drug Discovery Alliance With Janssen Biotech
January 10 2012

FORMA Therapeutics today announced an exclusive alliance with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies, in which the two companies will collaborate on the discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

view full story

Hydra Biosciences and Cubist Pharmaceuticals Announce Plans to Initiate Phase 1 Trial for Novel TRPA1 Modulator
January 10 2012

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Hydra Biosciences, Inc. today announced plans to begin a Phase 1 clinical trial for a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 (TRPA1) ion channel discovered in a collaboration between Cubist and Hydra.

view full story

Sutro Biopharma Announces Newly Formed Scientific Advisory Board
January 07 2012

Sutro Biopharma appointed James A. Wells, Ph.D., who has a depth of expertise and defining experience in protein engineering, and James R. Swartz, Sc.D., a leading expert in the field of cell-free protein synthesis, to the Sutro Scientific Advisory Board. Dr. Wells will serve as Chairman of the SAB

view full story

FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim
January 05 2012

FORMA Therapeutics announced a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer.

view full story

Viamet Initiates Phase 1 Prostate Cancer Clinical Trial
January 04 2012

Viamet Pharmaceuticals, Inc., announced that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer (CRPC). VT-464 is a novel, non-steroidal, small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile® Technology.

view full story

Receptos and Ono Establish Collaboration on Bioactive Lipid Discovery Research
December 12 2011

Receptos Inc. announced the establishment of a collaboration with Ono Pharmaceutical Co., Ltd. (Osaka, Japan) for the research and development of small molecule modulators of an undisclosed G–protein coupled receptor (GPCR) target. Under the terms of the agreement, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and drive Ono’s structure–based drug design efforts.

view full story

Aileron Announces Expansion of Roche Collaboration
November 16 2011

Aileron Therapeutics, Inc. announced the expansion of an existing drug discovery collaboration with Roche adding a third target in inflammatory disease to the existing oncology targets.

view full story

Cerulean Pharma Presents Phase 1/2a Lung Cancer Clinical Study of CRLX101
November 14 2011

Cerulean Pharma presented final data from the non-small cell lung cancer Phase 1/2a clinical study of CRLX101 at the AACR-NCI-EORTC conference. The drug was well tolerated at the maximum tolerated dose (MTD) and provided encouraging progression free survival (PFS) times.

view full story

Viamet Appoints Chief Medical Officer
November 03 2011

Viamet Pharmaceuticals Appoints Former Novartis Executive Marc Rudoltz, M.D. as Chief Medical Officer.

view full story

Gilead Licenses GlobeImmune HBV Program
October 24 2011

GlobeImmune and Gilead Announce Hepatitis B License and Collaboration Agreement.

view full story

Viamet Initiates Antifungal Clinical Trials
September 14 2011

Viamet Pharmaceuticals Initiates Phase 1 Clinical Trials for Best-in-Class Novel Antifungal VT-1161.

view full story

Forma Therapeutics Named One of the "Fierce 15" Leading Biotech Companies in 2011
September 06 2011

FORMA Therapeutics was named by FierceBiotech as one of the 2011 Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.

view full story

Cerulean Pharma Named One of the “Fierce 15” Leading Biotech Companies of 2011
September 06 2011

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, announced that FierceBiotech has named the Company one of 2011's Fierce 15 companies, designating it as one of the most promising private biotechnology companies in the industry.

view full story

Viamet and NIH to Develop Novel Anti-Fungal
July 28 2011

Viamet anti-fungal program was selected for inclusion by the National Institutes of Health program for Therapeutics for Rare and Neglected Diseases (TRND) Program.

view full story

Cerulean Initiates Randomized Phase 2 of CRLX101 in Non-Small Cell Lung Cancer
July 12 2011

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

view full story

Receptos Hires Industry Veteran as Chief Medical Officer
June 30 2011

Sheila Gujrathi, M.D., joins Receptos as Chief Medical Officer from Bristol-Meyers Squibb.

view full story

Nimbus Discovery Secures $24MM Series A Financing
June 28 2011

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24MM Series A financing. The investment was co-led by Atlas Venture, Lilly Ventures, and SR One.

view full story

FORMA Therapeutics Grants Genentech Exclusive Rights to Acquire a Pre-clinical Cancer Program
June 27 2011

FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.

view full story

GlobeImmune Reports Positive Results on Two Therapeutic Cancer Vaccines
June 01 2011

GlobeImmune announces safety and immunogenicity data from clinical trials in lung cancer with KRAS mutations and CEA expressing cancers.

view full story

Sutro's Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up
May 19 2011

Sutro Biopharma, which is developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, announced that a study published in the July issue of Biotechnology and Bioengineering demonstrates that the company’s biochemical protein synthesis technology platform enables fast and high-yield protein synthesis, scale-up, and straightforward purification by producing a fully bioactive, human, cytokine at titers of 700 mg/L in only 10 hours.

view full story

Cerulean Pharma Appoints Chief Medical Officer
May 17 2011

Cerulean Pharma Inc. appoints Edward Garmey, M.D. to serve as Chief Medical Officer and Senior Vice President.

view full story

Aileron Adds Industry R&D Veterans
April 11 2011

Aileron hires industry veteran Anthony Manning, Ph.D. as Senior Vice President of Research and Preclinical Development.

view full story

Cerulean Presents Phase 2a Oncology Clinical Data at AACR
April 04 2011

Cerulean presents Phase 2a interim clinical data that highlight observations of stable disease in advanced non-small cell lung carcinoma (NSCLC) patients.

view full story

Receptos Initiated Phase 1 Clinical Trial
January 27 2011

Receptos, Inc., announced today that their highly selective sphingosine-1-phosphate receptor 1 (S1P1) agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study.

view full story

Former FDA Commissioner Joins Viamet Board
January 19 2011

Andrew von Eschenbach, M.D., Former FDA Commissioner and Leading Prostate Cancer Expert, Elected to Viamet Pharmaceuticals Board of Directors.

view full story

Protagonist Establishes Partnership with Ironwood Pharmaceuticals
January 18 2011

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Protagonist Therapeutics, Inc. announced that they have entered into a collaboration to discover novel peptides for potential development by Ironwood. The collaboration capitalizes on Protagonist's proprietary disulfide rich peptide (DRP) technology platform, and provides Ironwood with the opportunity to develop novel peptides and treatments against clinically–validated targets in therapeutic areas with significant unmet medical needs.

view full story

Sutro Biopharma Forges Partnership with Pfizer
January 07 2011

Sutro Biopharma enters into a multiyear collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

view full story

Receptos in Exclusive Collaboration with Eli Lilly and Company
January 06 2011

Receptos announced an exclusive collaboration focused on structure determination and lead generation for a high value G-protein Coupled Receptor (GPCR) target.

view full story

Avid Closing Press Release
December 20 2010

Avid acquisition closes.

view full story

Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer
December 08 2010

Sutro Biopharma today announced that it has appointed Trevor Hallam, Ph.D., as Chief Scientific Officer (CSO). Dr. Hallam will lead Sutro's ongoing efforts in the application of the company's proprietary protein biochemical synthesis platform for the research and development of novel and biosuperior therapeutics.

view full story

Faheem Hasnain Named President and Chief Executive Officer of Receptos
December 02 2010

Industry veteran will strengthen Receptos’s clinical and commercial expertise in multiple sclerosis and expand activities including the potential to acquire additional focused therapeutic assets.

view full story

Eisai and FORMA Therapeutics Enter into Broad Drug Discovery Collaboration
November 17 2010

Eisai and FORMA Therapeutics announced a strategic drug discovery collaboration. Eisai will have non-exclusive access to FORMA's Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai's pipeline and an option for technology transfer of FORMA's cell-based screening platform.

view full story

GlobeImmune Announces Improves HCV End of Treatment Response in Phase 2b
October 20 2010

GlobeImmune Announces HCV End of Treatment Response in Phase 2b

view full story

Roche and Aileron Multi-target Deal
August 24 2010

Roche enters $1.1B deal with Aileron on up to five undisclosed targets in oncology, virology, inflammation, metabolism and central nervous system.

view full story

CGI to be Acquired by Gilead Sciences
July 14 2010

Gilead Science and CGI announce the signing of a Definitive Agreement whereby Gilead will acquire CGI.

view full story

Viamet Appoints Bill Moore as CSO
January 11 2010

Announced today that William Moore, Ph.D. has joined the company as Chief Scientific Officer.

view full story

Intradigm Merges with Silence Therapeutics
January 05 2010

Silence Therapeutics plc (“the Company”) (AIM: SLN) and Intradigm Corporation announce that the companies have completed their merger to form a leading company in the field of RNAi (RNA interference).

view full story